Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
19.77(c) 20.52(c) 21(c) 21.3(c) 21.23(c) Last
314 182 633 902 537 854 360 391 464 940 Volume
-0.70% +3.79% +2.34% +1.43% -0.33% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 179 M - -
Net income 2021 -144 M - -
Net cash position 2021 501 M - -
P/E ratio 2021 -11,3x
Yield 2021 -
Sales 2022 199 M - -
Net income 2022 -97,4 M - -
Net cash position 2022 362 M - -
P/E ratio 2022 -17,7x
Yield 2022 -
Capitalization 1 650 M 1 650 M -
EV / Sales 2021 6,44x
EV / Sales 2022 6,48x
Nbr of Employees 302
Free-Float 91,8%
More Financials
Company
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral... 
More about the company
Ratings of Dicerna Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about DICERNA PHARMACEUTICALS, INC.
10/15DICERNA PHARMACEUTICALS : Announces Data to Be Presented at American Society of Nephrology..
BU
10/14DICERNA PHARMACEUTICALS : to Present Phase 1 Data for Two Drug Candidates at Liver Disease..
MT
10/14DICERNA PHARMACEUTICALS : Announces Poster Presentations at American Association for the S..
BU
10/14Dicerna Pharmaceuticals, Inc. Announces Poster Presentations at American Association fo..
CI
10/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
10/01DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/29DICERNA PHARMACEUTICALS : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigati..
AQ
09/28DICERNA PHARMACEUTICALS : Begins Early-Stage Trial of Potential Treatment for Alcoholic Us..
MT
09/28DICERNA PHARMACEUTICALS : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigati..
BU
09/28Dicerna Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of DCR-AUD
CI
09/22DICERNA PHARMACEUTICALS : Names Rob Ciappenelli Chief Strategy Officer
MT
09/22DICERNA PHARMACEUTICALS : Announces New Executive Leadership Appointments
BU
09/22Dicerna Pharmaceuticals, Inc. Announces Executive Appointments
CI
09/21INSIDER SELL : Dicerna Pharmaceuticals
MT
09/07DICERNA PHARMACEUTICALS : Corporate Overview
PU
More news
News in other languages on DICERNA PHARMACEUTICALS, INC.
09/21VENTE D'INITIÉS : Dicerna Pharmaceuticals
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | DRNA | US2530311081 | MarketScreener
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 21,23 $
Average target price 30,89 $
Spread / Average Target 45,5%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagßn Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.-3.63%1 650
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156